Overview

Etomidate vs. Midazolam for Sedation During ERCP

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
Recently up-coming drug, etomidate which is a modulator of GABA(gamma-Aminobutyric acid)-A receptor has been known that it maintains the appropriate sedative levels and affects little effects on respiratory system. The investigators are now trying to investigate that etomidate with meperidine combination regimen is superior to the midazolam with meperidine more effective and less harm on sedation during the ERCP procedure.
Phase:
Phase 4
Details
Lead Sponsor:
Cheju Halla General Hospital
Treatments:
Etomidate
Meperidine
Midazolam